Clazosentan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clazosentan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clazosentan Today - Breaking & Trending Today

Idorsia Pharmaceuticals Ltd: Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - February 6, 2023 Idorsia Ltd (SIX: IDIA) today announces the initial findings of REACT, a Phase 3 study which investigated the ....

United States , Switzerland General , Andrewc Weiss , Jean Paul Clozel , Schwierige Zeiten , Idorsia Ltd , Head Of Investor Relations Corporate Communications , Idorsia Pharmaceuticals Ltd , Swiss Exchange , World Federation Of Neurological Societies , Paul Clozel , Chief Executive Officer , World Federation , Neurological Societies , North America , Lancet Neurology , Vice President , Investor Relations , Pharmaceuticals Ltd ,

The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected. | April 4, 2022 ....

Switzerland General , Japan General , Clin Neurosci , Andrewc Weiss , Satoshi Tanaka , Teiji Tominaga , Department Of Neurosurgery , Idorsia Ltd , Tohoku University Graduate School Of Medicine , Head Of Investor Relations Corporate Communications , Idorsia Pharmaceuticals Ltd , Idorsia Pharmaceuticals Japan , Swiss Exchange , Tohoku University Graduate School , Cerebral Vasospasm , Clipping Surgery , Aneurysmal Subarachnoid Hemorrhage , Pharmacol Exp , Lancet Neurology , Overcome Neurological Ischemia , Pharmaceuticals Japan , Vice President , Investor Relations , Pharmaceuticals Ltd , Idorsia Ltd Stock Exchange , Press Release ,

Idorsia Pharmaceuticals Ltd: The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety ....

Switzerland General , Japan General , Clin Neurosci , Andrewc Weiss , Satoshi Tanaka , Teiji Tominaga , Department Of Neurosurgery , Idorsia Ltd , Tohoku University Graduate School Of Medicine , Head Of Investor Relations Corporate Communications , Idorsia Pharmaceuticals Ltd , Idorsia Pharmaceuticals Japan , Swiss Exchange , Tohoku University Graduate School , Cerebral Vasospasm , Clipping Surgery , Aneurysmal Subarachnoid Hemorrhage , Pharmacol Exp , Lancet Neurology , Overcome Neurological Ischemia , Pharmaceuticals Japan , Vice President , Investor Relations , Pharmaceuticals Ltd ,

Idorsia Pharmaceuticals Ltd: Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg Allschwil, Switzerland - January 20, 2022Idorsia Ltd (SIX: IDIA) and ....

Switzerland General , Japan General , Andrewc Weiss , Satoshi Tanaka , Teiji Tominaga , Idorsia Ltd , Head Of Investor Relations Corporate Communications , Swiss Exchange , Department Of Neurosurgery , Tohoku University Graduate School Of Medicine , Japanese Pharmaceuticals , Idorsia Pharmaceuticals Ltd , Life Sciences , Idorsia Pharmaceuticals Japan , Devices Agency , Medical Devices Agency , Japanese Phase , Tohoku University Graduate School , Chief Executive Officer , Pharmacol Exp Ther , Pharmaceuticals Japan , Vice President , Investor Relations , Pharmaceuticals Ltd ,

Idorsia Pharmaceuticals Ltd: Idorsia submits NDA for clazosentan to Japanese PMDA

Idorsia Pharmaceuticals Ltd: Idorsia submits NDA for clazosentan to Japanese PMDA
Allschwil, Switzerland - March 1, 2021
Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ET
A) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH).
The application is supported by replicated results from the Japanese registration program which consisted of two double-blind, randomized, placebo-controlled studies assessing the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality events in adult Japanese patients following aSAH. Patients were randomized to receive continuous infusion of either 10 mg/hr clazosentan or placebo for up to 15 days following the ons ....

Switzerland General , Andrewc Weiss , Satoshi Tanaka , Idorsia Ltd , Head Of Investor Relations Corporate Communications , Swiss Exchange , Japanese Pharmaceuticals , Idorsia Pharmaceuticals Ltd , Life Sciences , Idorsia Pharmaceuticals Japan , Devices Agency , New Drug Application , Medical Devices Agency , Cerebrovascular Diseases , Pharmacol Exp Ther , Pharmaceuticals Japan , Vice President , Investor Relations , Pharmaceuticals Ltd , சுவிட்சர்லாந்து ஜநரல் , சதோஷி தனகா , தலை ஆஃப் முதலீட்டாளர் உறவுகள் பெருநிறுவன தகவல்தொடர்புகள் , சுவிஸ் பரிமாற்றம் , ஜப்பானிய மருந்துகள் , வாழ்க்கை அறிவியல் , புதியது மருந்து விண்ணப்பம் ,